US EditionPublished • loading... • Updated
Kirby McInerney LLP Reminds Baxter International, Inc. Investors of Class Action Filing and ...
The lawsuit alleges Baxter failed to disclose 79 injury reports and 2 deaths linked to Novum IQ pump defects, causing a 22.4% stock drop, according to filings.
- A New York press release on Oct. 17, 2025, alleges Baxter misled investors about Novum LVP safety issues during the period ending April 24, 2025.
- A Missouri news outlet reported whistleblower allegations, and Baxter issued warnings on April 24 and July 14, 2025, about infusion risks.
- Baxter logged 79 serious-injury reports and two deaths tied to the Novum LVP, and the Action alleges defects caused underinfusion and non-delivery, triggering a 22.4% share decline on July 31, 2025.
- Kirby McInerney LLP reminded Baxter investors of the December 15, 2025 deadline to seek lead-plaintiff status and invited contact with Thomas W. Elrod or Lauren Molinaro, Esq. at 212-699-1171 or investigations@kmllp.com for no-cost consultations.
- The suit alleges Baxter's customer alerts were inadequate remedial measures while design flaws persisted, following whistleblower-driven media coverage raising patient safety oversight and investor concerns.
Insights by Ground AI
68 Articles
68 Articles
Baxter faces investor lawsuit over infusion pumps
Investors have filed a lawsuit claiming Baxter (NYSE:BAX) violated federal securities laws as a result of issues with certain infusion pumps. Bloomberg Law first reported the filing of the lawsuit in Illinois. The class action suit seeks a trial by jury as investors hope to recover damages related to the rollout of its Novum IQ large-volume infusion pump (LVP). It pertains to those who acquired Baxter common stock between Feb. 23, 2022, and July…
Coverage Details
Total News Sources68
Leaning Left6Leaning Right5Center24Last UpdatedBias Distribution69% Center
Bias Distribution
- 69% of the sources are Center
69% Center
L 17%
C 69%
14%
Factuality
To view factuality data please Upgrade to Premium
